Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03557658 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment
A Phase 1 study, sponsored by Theracos.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03557658 is a Phase 1 study that has completed, run by Theracos. The registered enrollment target is 16 participants.
The verdict
NCT03557658, a Phase 1 study, has completed, sponsored by Theracos.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the drug exposure and drug effects on subjects with moderate hepatic impairment after a single oral dose of bexagliflozin tablets, 20mg. The study will also evaluate how safe the study drug is and how well the study drug is tolerated in subjects with moderate hepatic impairment.
Interventions
- DRUG Bexagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-07-26 |
| Est. Completion | 2018-12-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03557658
The ClinicalTrials.gov registry entry for NCT03557658 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theracos, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bexagliflozin is the first listed.
NCT03557658 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03557658 about?
NCT03557658 is a clinical study titled "Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment". The purpose of this study is to examine the drug exposure and drug effects on subjects with moderate hepatic impairment after a single oral dose of bexagliflozin tablets, 20mg. The study will also evaluate how safe the study drug is and how well the study drug is tolerated in subjects with moderate ...
What is the current status of trial NCT03557658?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-07-26. Estimated completion is 2018-12-26.
What interventions are being tested in trial NCT03557658?
The interventions under investigation include: Bexagliflozin (DRUG).
Who is sponsoring clinical trial NCT03557658?
This trial is sponsored by Theracos, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.